Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

PCSK9 inhibitors are another medication. “PCSK9 inhibitors are drugs that block the PCSK9 protein, which reduces LDL receptor ...

Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

Both types are effective at managing cholesterol, but researchers have uncovered some surprising side effects. Weight Gain: Some people taking statins might gain weight or body fat. Hormone Changes: ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

so they don’t have that same effect of causing liver damage. PCSK9 inhibitors are a new class of medications that may be available to patients to help reduce their cholesterol. By inhibiting a ...

To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.